NEWS
Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of ZTlido® Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets in Far East Region
Scilex Holding Company (Nasdaq: SCLX) has entered a Memorandum of Understanding (MOU) with ACEA Therapeutics for collaboration on ZTlido®, a lidocaine topical system for neuropathic pain relief. The agreement grants ACEA exclusive rights to develop and commercialize ZTlido® in Greater China, including mainland China, Taiwan, Hong Kong, and Macau. ACEA will serve as the exclusive distributor in these territories, with a potential minimum purchase commitment once ZTlido® is locally approved.
The collaboration aims to expand Scilex's non-opioid pain management portfolio in the Greater China region. The pain management market in mainland China was valued at US$17.5 billion in 2022, with an annual growth rate of 5.64%. This partnership aligns with Scilex's mission to provide innovative non-opioid medicines to acute and chronic pain patients worldwide.
The collaboration aims to expand Scilex's non-opioid pain management portfolio in the Greater China region. The pain management market in mainland China was valued at US$17.5 billion in 2022, with an annual growth rate of 5.64%. This partnership aligns with Scilex's mission to provide innovative non-opioid medicines to acute and chronic pain patients worldwide.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1073Followers
68Following
7371Visitors
Follow